Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, Madrigal Pharmaceuticals, Inc. has 23.09M shares outstanding.

As of June 30, 2026, Madrigal Pharmaceuticals, Inc. maintains a current ratio of 3.20, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 66.40, indicating elevated leverage, while an interest coverage ratio of -10.19 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Madrigal Pharmaceuticals, Inc. posted a negative return on equity (ROE) of -53.31, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -28.77, reflecting losses generated across the asset base. The company generates approximately 1.27M in revenue per employee across its workforce of 818.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.34 indicates how many times Madrigal Pharmaceuticals, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 20, 2026, Madrigal Pharmaceuticals, Inc.'s stock has gained approximately 2.77% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Madrigal Pharmaceuticals, Inc. generated 1.04B in revenue and converted that into -262.62M in net income, yielding earnings per share of -10.15. EBITDA reached -259.39M, while operating income came in at -260.62M.

As of June 30, 2026, Madrigal Pharmaceuticals, Inc. holds 677.57M in cash and equivalents against 280.92M in total debt, resulting in a net debt position of 38.83M. Total book value stands at 423.08M, with working capital of 666.44M providing operational flexibility.

Madrigal Pharmaceuticals, Inc. produced -159.72M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -9.35M in capital expenditures, free cash flow totaled -169.07M - equivalent to -6.53 per share.

Over the twelve months ended June 30, 2026, Madrigal Pharmaceuticals, Inc. posted a gross margin of 91.48, reflecting its pricing power and cost economics. The operating margin of -25.13 and net profit margin of -25.32 provide insight into operational efficiency.

Madrigal Pharmaceuticals, Inc.'s most recent stock split took place on July 25, 2016 with a 35:1 split ratio.